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background:  The recent prevention guidelines by the ACC/AHA have shifted away from low-density lipoprotein cholesterol targets and 
instead recommend fixed dose high potency statin (HPS) therapy for patients with established atherosclerotic cardiovascular disease 
(ASCVD). We sought to determine practice patterns at the Veterans Affairs (VA) Health System prior to the release of these guidelines in 
order to identify areas for improvement.
Methods:  We examined administrative data from the VA from 7/1/2012 to 12/31/2012 to identify patients with at least one outpatient visit 
for a diagnosis of established ASCVD, defined as coronary heart disease, cerebrovascular disease, or peripheral arterial disease. HPS was 
defined as atorvastatin 40mg or 80mg, rosuvasatin 20mg or 40mg and simvastatin 80mg. Patient and facility-level predictors of statin use 
for secondary prevention were analyzed using multivariate logistic regressions.
Results:  Our study sample included 569,009 eligible adults with established ASCVD, including 11,380 (2%) women and 108,111 (19%) 
non-white patients. Almost thirty percent of eligible patients were not taking any statin and only 16% were taking HPS. After adjusting for 
clinical covariates, older patients (Odds Ratios [OR]=0.74; 95% CI 0.74-0.75 per each 10 year increase) and women (OR=0.83; 95% CI 
0.78-0.88) were less likely to be on a HPS. Similarly, as compared with whites, Hispanic (OR=0.84; 95% CI 0.81-0.88) and black (OR 
=0.91; 95% CI 0.88-0.92) patients were less likely to on a HPS. Recent history of ischemic heart disease was a strong predictor of HPS use 
(OR=2.13; 95% CI 2.08-2.19). Academic (Council on Teaching) hospitals were more likely to prescribe HPS to eligible patients (OR=1.13; 
95% CI 1.10-1.15).
conclusion:  Prior to the new ACC/AHA prevention guideline, only 16% of Veterans with established ASCVD were receiving HPS and 
some patient groups, namely older adults, certain minorities, and women, were less likely to be prescribed HPS. These findings suggest 
that a large change in practice is needed for current guideline compliance, with targeted efforts for particularly vulnerable patient groups.
